Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Dec. 11, 2014, 103 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $337.00 to $15,638,127.00.

Highlighted Stocks Traded by Insiders:

Cancer Genetics (CGIX) - FREE Research Report

Pappajohn John, who is Director at Cancer Genetics, bought 5,773 shares at $5.96 on Dec. 11, 2014. Following this transaction, the Director owned 1.4 million shares meaning that the stake was boosted by 0.41% with the 5,773-share transaction.

The shares most recently traded at $6.30, up $0.34, or 5.4% since the insider transaction. Historical insider transactions for Cancer Genetics go as follows:

  • 4-Week # shares bought: 39,686
  • 12-Week # shares bought: 39,686
  • 24-Week # shares bought: 39,686

The average volume for Cancer Genetics has been 54,300 shares per day over the past 30 days. Cancer Genetics has a market cap of $55.6 million and is part of the health care sector and health services industry. Shares are down 55.15% year-to-date as of the close of trading on Wednesday.

Cancer Genetics, Inc., an early-stage diagnostics company, focuses on developing and commercializing proprietary genomic tests and services to improve and personalize the diagnosis, prognosis, and response to treatment of cancer. Currently, there are 2 analysts who rate Cancer Genetics a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CGIX - FREE

TheStreet Quant Ratings

rates Cancer Genetics as a

sell

. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, poor profit margins and generally disappointing historical performance in the stock itself. Get the full

Cancer Genetics Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

NovaBay Pharmaceuticals (NBY) - FREE Research Report

Paulson Thomas J, who is Cfo at NovaBay Pharmaceuticals, bought 10,000 shares at $0.67 on Dec. 11, 2014. Following this transaction, the Cfo owned 58,210 shares meaning that the stake was boosted by 20.74% with the 10,000-share transaction.

Najafi Ramin, who is Chief Executive Officer at NovaBay Pharmaceuticals, bought 20,000 shares at $0.60 on Dec. 11, 2014. Following this transaction, the Chief Executive Officer owned 3.2 million shares meaning that the stake was boosted by 0.63% with the 20,000-share transaction.

Historical insider transactions for NovaBay Pharmaceuticals go as follows:

  • 4-Week # shares bought: 43,000
  • 4-Week # shares sold: 30,000
  • 12-Week # shares bought: 43,000
  • 12-Week # shares sold: 30,000
  • 24-Week # shares bought: 43,000
  • 24-Week # shares sold: 30,000

The average volume for NovaBay Pharmaceuticals has been 138,200 shares per day over the past 30 days. NovaBay Pharmaceuticals has a market cap of $32.9 million and is part of the health care sector and drugs industry. Shares are down 48.25% year-to-date as of the close of trading on Wednesday.

NovaBay Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing product candidates for the therapeutic needs of anti-infective market. The company operates in four segments: Dermatology, Ophthalmology, Urology, and Wound Care. Currently, there are no analysts who rate NovaBay Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NBY - FREE

TheStreet Quant Ratings

rates NovaBay Pharmaceuticals as a

sell

. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full

NovaBay Pharmaceuticals Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

BioAmber (BIOA) - FREE Research Report

Wall Kenneth W., who is Director at BioAmber, bought 3,000 shares at $9.20 on Dec. 11, 2014. Following this transaction, the Director owned 8,000 shares meaning that the stake was boosted by 60% with the 3,000-share transaction.

The shares most recently traded at $8.46, down $0.74, or 8.75% since the insider transaction. Historical insider transactions for BioAmber go as follows:

  • 4-Week # shares bought: 5,000
  • 12-Week # shares bought: 20,000
  • 24-Week # shares bought: 49,430

The average volume for BioAmber has been 60,200 shares per day over the past 30 days. BioAmber has a market cap of $203.5 million and is part of the basic materials sector and chemicals industry. Shares are up 18.05% year-to-date as of the close of trading on Wednesday.

BioAmber Inc., an industrial biotechnology company, produces and sells bio-succinic acid to customers in various chemical markets in the United States. Currently, there are 2 analysts who rate BioAmber a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BIOA - FREE

TheStreet Quant Ratings

rates BioAmber as a

sell

. Among the areas we feel are negative, one of the most important has been an overall disappointing return on equity. Get the full

BioAmber Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null